Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New Control System Of The Body Discovered - Important Modulator Of Immune Cell Entry Into The Brain - Perhaps New Target For The Therapy
Researchers in Berlin, Germany have ameliorated inflammation of the brain in mice caused by immune cells. A receptor they discovered on the surface of T cells in the central nervous system (CNS) plays the key role. The researchers showed that this bradykinin receptor 1 (B1) controls the infiltration of immune cells into the CNS. When they activated B1 in mice with encephalitis, they were able to slow down the crossing of the immune cells through the blood-brain-barrier into the CNS. As a result, the inflammation markedly decreased. The work by Dr. Ulf Schulze-Topphoff, Prof. Orhan Aktas, and Professor Frauke Zipp (Cecilie Vogt-Clinic, Charité - Universitätsmedizin Berlin, Max DelbrÃøck Center for Molecular Medicine (MDC) Berlin-Buch and NeuroCure Research Center) together with researchers in Canada and the USA may unveil a new target for the treatment of chronic inflammatory diseases such as multiple sclerosis (MS) (Nature Medicine, doi 10.1038/nm.1980)*.

'We Want Sex, Not AIDS'
Health workers fail to understand the importance of sex for Tanzanian children
News of the day
CDC Report Examines Sexual Health, AIDS Rates Among U.S. Teenagers, Young Adults
CDC"s latest Morbidity and Mortality Weekly Report (MMWR) examines the sexual health of young adults and teenagers in the U.S., Reuters reports. "The data presented in this report indicate that many young persons in the United States engage in sexual risk behavior and experience negative reproductive health outcomes," the MMWR states (7/16). For the report, CDC compiled data from several different studies involving hundreds of thousands of teenagers and young adults age 10 to 25. Among other findings, the data indicated that AIDS rates among boys age 15 to 19 increased from 1.3 cases per 100,000 in 1997 to 2.5 cases in 2006. The report also said that new HIV and AIDS diagnoses were highest among young blacks across all age groups (Chicago Tribune, 7/17). Kevin Fenton, director of CDC"s National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention, said, "It is imperative that all of us at the national and community level work together to ensure STD and HIV prevention programs are reaching young people, particularly in communities with the greatest burden of disease" (Brewington, "Picture of Health," Baltimore Sun, 7/16).
Mental Health

Indiana University School Of Medicine Researchers Develop Promising New Cancer Diagnostic Marker

Indiana University School of Medicine researchers have developed a new breast cancer diagnostic marker that could enable physicians to more easily determine which patients have a less aggressive form of the disease that may not require chemotherapy treatment. The marker has been licensed by Clarient Inc., a California-based cancer diagnostics company that plans to develop a commercial test based on the research by Harikrishna Nakshatri, B.V.Sc., Ph.D., Marian J. Morrison Professor of Breast Cancer Research, and Sunil Badve, M.D., associate professor of pathology and laboratory medicine. In two studies involving nearly 675 patients, Nakshatri and Badve found that patients who tested positive for the presence of the biomarker - a protein called FOXA1 - were patients whose cancer is generally considered less aggressive. About 70 percent of breast cancer patients have tumors that are "estrogen receptor positive," meaning that the hormone estrogen stimulates the tumors to grow. However, nearly two-thirds of the estrogen receptor positive patients have a subtype that is less aggressive and is associated with a better prognosis - most of whom also tested positive for the FOXA1 biomarker. A commercial test based on the biomarker - for which IU and the IU School of Medicine researchers are seeking a patent - could be a significantly less expensive alternative to existing methods to test for breast cancer subtypes that require sophisticated genomic analyses. "This is something that 80 percent of surgical pathology labs up and down the country could do," said Dr. Badve. "Even in a developing country, a third-world country, these things can be easily done," said Dr. Nakshatri. Those patients who test positive for the biomarker are more likely to respond to anti-estrogen hormone therapies, such as tamoxifen, the researchers said. For other patients the standard of care would be chemotherapy. The IU researchers, working with scientists in North Carolina, Canada, Britain and Italy, tested the diagnostic capabilities of the FOX1A biomarker in two retrospective studies - meaning that tests were conducted on tissue samples from patients who had been treated for breast cancer. The first study, published in the Aug. 1, 2007, edition of Clinical Cancer Research, studied samples from 438 patients with a median of more than 15.4 years of followup. A second study, of 245 cases with a median followup of more than 5 years, was published in the Nov. 15, 2007, edition of the Journal of Clinical Pathology. Data from a third study, with 4,000 cases, was recently completed in collaboration with researchers at the University of British Columbia and data from the research are being analyzed. Financial support for the research was provided by the National Institutes of Health, including the National Cancer Institute, Sanofi-Aventis and Breakthrough Breast Cancer. Indiana University School of Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009